miRNAs: micro-managers of anticancer combination therapies

Judy R van Beijnum, Elisa Giovannetti, Dennis Poel, Patrycja Nowak-Sliwinska, Arjan W Griffioen

Research output: Contribution to journalReview articleAcademicpeer-review

55 Citations (Scopus)


Angiogenesis is one of the hallmarks of cancer progression and as such has been considered a target of therapeutic interest. However, single targeted agents have not fully lived up to the initial promise of anti-angiogenic therapy. Therefore, it has been suggested that combining therapies and agents will be the way forward in the oncology field. In recent years, microRNAs (miRNAs) have received considerable attention as drivers of tumor development and progression, either acting as tumor suppressors or as oncogenes (so-called oncomiRs), as well as in the process of tumor angiogenesis (angiomiRs). Not only from a functional, but also from a therapeutic view, miRNAs are attractive tools. Thus far, several mimics and antagonists of miRNAs have entered clinical development. Here, we review the provenance and promise of miRNAs as targets as well as therapeutics to contribute to anti-angiogenesis-based (combination) treatment of cancer.

Original languageEnglish
Pages (from-to)269-285
Number of pages17
Issue number2
Publication statusPublished - May 2017


  • Animals
  • Antineoplastic Combined Chemotherapy Protocols/therapeutic use
  • Humans
  • MicroRNAs/metabolism
  • Neoplasms/blood supply
  • Neovascularization, Pathologic/drug therapy
  • RNA, Neoplasm/metabolism

Cite this